GELAD化疗联合夹心放疗治疗新诊断IE/IIE期自然杀伤/T细胞淋巴瘤患者:一项前瞻性多中心研究
这项前瞻性多中心研究纳入52例新诊断IE/IIE期自然杀伤/T细胞淋巴瘤患者,采用两周期GELAD化疗后行调强放疗(50-56 Gy/25-28次)再行两周期GELAD化疗。总缓解率94.2%,完全缓解率92.3%;中位随访32个月,估计4年总生存率94.2%,无进展生存率90.4%。
要点
- GELAD方案联合夹心放疗在早期NK/TCL中总缓解率94.2%、完全缓解率92.3%。
- 中位随访32个月,估计4年总生存率94.2%、无进展生存率90.4%。
- 最常见不良事件与培门冬酶相关,3/4级中性粒细胞减少发生率15.4%。
核心结论
- 本研究为早期NK/TCL患者提供了一种高活性且安全性改善的新治疗方法。
研究设计与样本
- 前瞻性多中心研究,纳入新诊断IE/IIE期NK/TCL患者52例。
主要发现
- 按Lugano 2014标准,总缓解率为94.2%,完全缓解率为92.3%。
- 中位随访32个月,估计4年总生存率为94.2%(95%CI 83.2%至93.1%),估计4年无进展生存率为90.4%(95%CI 78.4%至95.9%)。
- 最常见不良事件与培门冬酶相关;血液学毒性较轻,3/4级中性粒细胞减少发生率为15.4%。
关键数值与推荐
- 治疗方案:先予两周期GELAD方案(吉西他滨1.0 g/m²第1天,依托泊苷60 mg/m²第1-3天,培门冬酶2000 units/m²第4天,地塞米松40 mg第1-4天),后行调强放疗(50-56 Gy,25-28次),再予两周期GELAD化疗。
- 疗效评价采用Lugano 2014标准,总缓解率94.2%,完全缓解率92.3%。
- 研究注册号:NCT02733458。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early-stage natural killer/T-cell lymphoma (NK/TCL) patients usually receive a combination of chemotherapy and radiotherapy, but the optimal treatment approach has not yet been established. This study aimed to investigate the efficacy and safety profile of a novel chemotherapy regimen and sandwiched radiotherapy in early-stage NK/TCL. Patients with newly diagnosed stage IE/IIE disease were eligible. Patients were initially treated with two courses of the GELAD regimen (gemcitabine 1·0 g/m2 day 1, etoposide 60 mg/m2 days 1-3, pegaspargase 2000 units/m2 day 4, and dexamethasone 40 mg days 1-4), followed by intensity-modulated radiotherapy (IMRT; 50-56 Gy in 25-28 fractions) and two additional courses of GELAD chemotherapy. A total of 52 patients were enrolled. The overall response rate and complete response rate per Lugano 2014 criteria were 94·2% and 92·3% respectively. With a median follow-up of 32 months, the estimated four-year overall survival rate and progression-free survival rate were 94·2% [95% confidence interval (CI), 83·2% to 93·1%] and 90·4% (95% CI, 78·4% to 95·9%) respectively. The most common adverse events were related to pegaspargase. Haematological toxicities were mild, with grade 3/4 neutropenia in 15·4% of patients. Our study provides a new approach with high activity and improved safety for the treatment of early-stage NK/TCL patients. This study was registered at www.clinicaltrials.gov as NCT02733458.
引用
- Zhu Y, Tian S, Xu L, et al. GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study. Br J Haematol. 2021. PMID: 34806163. doi:10.1111/bjh.17960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。